L3VLUP
ProSign in

EDIT · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

EDITARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • EDIT
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterEDITARGX
Q3 20205 holders, $378m8 holders, $3.6bn
Q4 20206 holders, $969m7 holders, $4.1bn
Q1 20217 holders, $498m8 holders, $4.1bn
Q2 20216 holders, $540m9 holders, $4.6bn
Q3 20215 holders, $349m8 holders, $4.5bn
Q4 20215 holders, $178m9 holders, $5.3bn
Q1 20226 holders, $86m8 holders, $5.3bn
Q2 20226 holders, $41m13 holders, $6.5bn
Q3 20225 holders, $42m14 holders, $5.3bn
Q4 20225 holders, $29m13 holders, $5.5bn
Q1 20233 holders, $20m13 holders, $5.9bn
Q2 20234 holders, $47m18 holders, $6.6bn
Q3 20234 holders, $44m21 holders, $8.7bn
Q4 20233 holders, $21m17 holders, $6.3bn
Q1 20242 holders, $7.0m13 holders, $6.8bn
Q2 20243 holders, $6.3m14 holders, $7.9bn
Q3 20242 holders, $3.5m13 holders, $10.7bn
Q4 2024none listed holders, n.a.14 holders, $12.3bn
Q1 2025none listed holders, n.a.17 holders, $11.8bn
Q2 2025none listed holders, n.a.18 holders, $10.8bn
Q3 2025none listed holders, n.a.16 holders, $13.8bn
Q4 2025none listed holders, n.a.16 holders, $14.8bn
Q1 2026none listed holders, n.a.11 holders, $12.3bn
Q2 20261 holders, $12m14 holders, $15.0bn
EDIT

Editas Medicine Inc

Holders
0
Reported value
$0
Buyers
0
Sellers
1

Not ranked this quarter: its new positions are allocations in a new listing.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
14
Reported value
$12.3bn
Buyers
8
Sellers
6

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2024

Among the 14 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only EDIT (0)

None.

Only ARGX (14)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Fidelity (FMR LLC), Holocene Advisors LP, Janus Henderson Group Ltd, Marshall Wace LLP, Moore Capital Management LP, Point72 Asset Management LP, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →